Dr Rohit
Vol. 1, Issue 1, Jan-Jun 2016
Abstract:
Alzheimer’s disease (AD), a neurodegenerative disease and leading cause of dementia, has emerged as a major public health challenge for ageing populations all over the world. The characteristic pathological changes are of irreversible neuronal loss, and deposition of plaques laden with amyloid-β peptide; and neurofibrillary tangles made up of abnormally hyperphosphorylated tau protein in critical areas of brain have been well established (Hardy J, Selkoe DJ Science. 2002 Jul 19; 297(5580):353-6.). The poor understanding of the pathogenesis of AD and consequent lack of definitive therapy provides opportunity for development of newer diagnostic and treatment strategies. The search for biomarkers to aid accurate diagnosis, predict progression and for use in clinical trials has become a major research goal. (Expert Rev Proteomics. 2007 Apr; 4(2):227-38.) The most widely used strategy for the discovery of biomarkers is predicated on the identification of potential candidate biomarkers using knowledge of disease processes followed by validation, comparing healthy control to affected subjects
Disclaimer: Indexing of published papers is subject to the evaluation and acceptance criteria of the respective indexing agencies. While we strive to maintain high academic and editorial standards, International Journal of Research in Medical Sciences and Technology does not guarantee the indexing of any published paper. Acceptance and inclusion in indexing databases are determined by the quality, originality, and relevance of the paper, and are at the sole discretion of the indexing bodies.